The team


Dr Anna Schuh, MD, PhD, MRCP, FRCPath

Dr Anna Schuh is a consultant haematologist at Oxford University Hospitals. Her main research interests are with chronic lymphocytic leukaemia (CLL) and molecular diagnostics. She is a principle/chief investigator on a number of early and late Phase clinical trials in CLL. As the Head of the MDC, she leads on a translational research programme for the development, validation, standardisation and evaluation of clinical utility of NGS technologies. Her particular focus is with improving response prediction in CLL and other malignancies using whole genome sequencing. She receives grants from NIHR, Wellcome Trust and the Technology Strategy Board. She is an active member of the NCRN CLL subgroup and the NCRN biomarker and imaging group.

 

Dr Wale Atoyebi, MBBS, FRCP, FRCPath

Dr Wale Atoyebi is Consultant Haematologist at Oxford University Hospitals and Honorary Senior Clinical Lecturer at University of Oxford. His main interest is in the diagnosis and management of  red cell disorders including haemoglobin disorders  and disorders of iron metabolism.

 

Dr Noémi Roy, MBChB, BSc, DPhil, MRCP, FRCPath

Noémi is a haematology consultant at the Oxford University Hospitals NHS Foundation Trust.  She has an interest in rare inherited anaemias and leads the targeted next-generation sequencing investigation for inherited anaemias in Oxford.  She is also a member of the genomics MDT in Oxford and co-chair of the red cell genomics MDT for the NIHR Bioresource SMD (stem and myeloid) project. Her main area of clinical focus and research is in inherited anaemias including haemoglobinopathies and rare inherited anaemias.  In addition she is actively involved in research into the commonest form of anaemia, iron deficiency.  By focusing on the role of serum hepcidin in the management of iron deficiency in a variety of clinical contexts, including intensive care, pre-operative anaemia and the anaemia of pregnancy, the research team aims to improve the approach by which iron deficiency is treated to provide optimal clinical efficacy in these patient groups.  Noémi is a member of the British Society of Haematology General Haematology Task force and the European Haematology Association Guidelines Committee Executive Group.

 

© 2018 Oxford Molecular Diagnostic Centre. All rights reserved.

Last updated 21 May 2018